 Perrigo Co. Plc said Monday it has agreed to sell its generic business to Altaris Capital Partners LLC for 1.55 billion, including 1.5 billion in cash. Altaris will assume more than 50 million in potential milestone payments and contingent purchase obligations with third-party Rx partners. 